Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in Vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2014 May 1

PMID 24782868

Citations 81

Authors

Florian Wimmers

Gerty Schreibelt

Annette E Skold

Carl G Figdor

I Jolanda M de Vries

Affiliations

Soon will be listed here.

Abstract

Dendritic cell (DC)-based immunotherapy employs the patients' immune system to fight neoplastic lesions spread over the entire body. This makes it an important therapy option for patients suffering from metastatic melanoma, which is often resistant to chemotherapy. However, conventional cellular vaccination approaches, based on monocyte-derived DCs (moDCs), only achieved modest response rates despite continued optimization of various vaccination parameters. In addition, the generation of moDCs requires extensive ex vivo culturing conceivably hampering the immunogenicity of the vaccine. Recent studies, thus, focused on vaccines that make use of primary DCs. Though rare in the blood, these naturally circulating DCs can be readily isolated and activated thereby circumventing lengthy ex vivo culture periods. The first clinical trials not only showed increased survival rates but also the induction of diversified anti-cancer immune responses. Upcoming treatment paradigms aim to include several primary DC subsets in a single vaccine as pre-clinical studies identified synergistic effects between various antigen-presenting cells.

Citing Articles

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.

Zhao C, Jia B, Jiang Y, Shike H, Annageldiyev C, Cioccio J Cancer Immunol Immunother. 2025; 74(4):117.

PMID: 39998689 PMC: 11861774. DOI: 10.1007/s00262-025-03971-y.

Overcoming Resistance Mechanisms to Melanoma Immunotherapy.

Zheng D, Bozym D, Tarantino G, Sullivan R, Liu D, Jenkins R Am J Clin Dermatol. 2024; 26(1):77-96.

PMID: 39636504 DOI: 10.1007/s40257-024-00907-7.

New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells.

Silva Z, Rabaca J, Luz V, Lourenco R, Salio M, Oliveira A Cancer Immunol Immunother. 2024; 74(1):9.

PMID: 39487861 PMC: 11531459. DOI: 10.1007/s00262-024-03863-7.

Bibliometric analysis of dendritic cell-based vaccines over the past 15 years.

Long Z, Wu Y, Zhong L, Lu J, Liu B Hum Vaccin Immunother. 2024; 20(1):2392961.

PMID: 39161160 PMC: 11340764. DOI: 10.1080/21645515.2024.2392961.

Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines.

Palomares F, Pina A, Dakhaoui H, Leiva-Castro C, Munera-Rodriguez A, Cejudo-Guillen M Vaccines (Basel). 2024; 12(2).

PMID: 38400148 PMC: 10891551. DOI: 10.3390/vaccines12020165.

References

Robert C, Thomas L, Bondarenko I, ODay S, Weber J, Garbe C . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-26. DOI: 10.1056/NEJMoa1104621. View

Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H . Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994; 24(3):605-10. DOI: 10.1002/eji.1830240317. View

Tel J, Schreibelt G, Sittig S, Mathan T, Buschow S, Cruz L . Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood. 2012; 121(3):459-67. DOI: 10.1182/blood-2012-06-435644. View

MacDonald K, Munster D, Clark G, Dzionek A, Schmitz J, Hart D . Characterization of human blood dendritic cell subsets. Blood. 2002; 100(13):4512-20. DOI: 10.1182/blood-2001-11-0097. View

Haanen J, Baars A, Gomez R, Weder P, Smits M, de Gruijl T . Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother. 2005; 55(4):451-8. PMC: 11030194. DOI: 10.1007/s00262-005-0018-5. View

Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

de Vries E, Coebergh J . Melanoma incidence has risen in Europe. BMJ. 2005; 331(7518):698. PMC: 1226263. DOI: 10.1136/bmj.331.7518.698. View

Van Nuffel A, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B . Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother. 2011; 61(7):1033-43. PMC: 11028719. DOI: 10.1007/s00262-011-1176-2. View

Lozza L, Farinacci M, Fae K, Bechtle M, Staber M, Dorhoi A . Crosstalk between human DC subsets promotes antibacterial activity and CD8+ T-cell stimulation in response to bacille Calmette-Guérin. Eur J Immunol. 2013; 44(1):80-92. PMC: 3992850. DOI: 10.1002/eji.201343797. View

10.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

11.

Tel J, Anguille S, Waterborg C, Smits E, Figdor C, de Vries I . Tumoricidal activity of human dendritic cells. Trends Immunol. 2013; 35(1):38-46. PMC: 7106406. DOI: 10.1016/j.it.2013.10.007. View

12.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

13.

Faiola B, Doyle C, Gilboa E, Nair S . Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells. Immunology. 2002; 105(1):47-55. PMC: 1782635. DOI: 10.1046/j.0019-2805.2001.01343.x. View

14.

Jonuleit H, Tuting T, Stuge T, Paragnik L, Kandemir A, Lee P . A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001; 93(2):243-51. DOI: 10.1002/ijc.1323. View

15.

Mathan T, Figdor C, Buschow S . Human plasmacytoid dendritic cells: from molecules to intercellular communication network. Front Immunol. 2013; 4:372. PMC: 3825182. DOI: 10.3389/fimmu.2013.00372. View

16.

Dennis L . Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999; 135(3):275-80. DOI: 10.1001/archderm.135.3.275. View

17.

Creagan E, Ahmann D, Green S, Long H, Rubin J, SCHUTT A . Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer. 1984; 54(12):2844-9. DOI: 10.1002/1097-0142(19841215)54:12<2844::aid-cncr2820541205>3.0.co;2-q. View

18.

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

19.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

20.

Engell-Noerregaard L, Hansen T, Andersen M, Straten P, Marie Svane I . Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2008; 58(1):1-14. PMC: 11030652. DOI: 10.1007/s00262-008-0568-4. View